The Pipeline
Our two clinical-stage product candidates, Inupadenant (EOS-850) and EOS-448, each target a key mechanism that inhibits an effective antitumor immune response: the ATP adenosine pathway and a novel checkpoint TIGIT, respectively. We believe that both product candidates have the potential to further increase patient responses to standard cancer therapies, including immunotherapy. We are evaluating numerous biomarkers in our clinical programs to maximize this potential through choosing synergistic combination agents and identifying patients most likely to benefit from our product candidates.
We are also using our deep understanding of the critical immune resistance pathways to identify new targets and generate additional differentiated programs for underexploited pathways validated by a strong scientific rationale.
Pipeline
Program | Trial Design | Indications | Preclinical | Phase 1 | Phase 1b/2a | Key upcoming milestones | |
---|---|---|---|---|---|---|---|
Adenosine Pathway
|
A2A Receptor Antagonist | ||||||
Inupadenant (EOS-850)
|
Monotherapy | Solid tumors | Initial expansion results 1H 2021 | ||||
+ pembrolizumab | PD-1-Resistant Melanoma | Initiated 3Q 2020 | |||||
+ pembrolizumab | Castrate-R Prostate Cancer | Initiated 3Q 2020 | |||||
+ Pac-Carbo | TNBC | Initiated 3Q 2020 | |||||
Treg Targeting
|
Anti-TIGIT mAb ADCC-enabled | ||||||
EOS-448
|
Dose Finding, PK/PD | Solid tumors | Presentation of initial results 1H 2021 | ||||
Mono / + Combo | Multiple Myeloma | Initiation mid-2021 | |||||
+ PD-(L)1 | NSCLC | Initiation mid-2021 | |||||
Inupadenant +/- Chemo | Solid Tumors | Initiation mid-2021 | |||||
Preclinical pipeline
|
Preclinical pipeline | ||||||
Adenosine Pathway Inhibitor
|
Oncology | Candidate selection in 2021 |